Jul. 17 at 12:54 PM
STAAR Surgical fell in premarket trading after reporting preliminary Q2 2026 net sales of more than
$90 million, more than double the
$44.3 million reported a year ago but largely in line with Wall Street expectations of
$90.2 million. The lack of a meaningful revenue beat triggered a "sell-the-news" reaction, sending shares down more than 8% after hours before partially recovering.
Canaccord Genuity reiterated its Buy rating and
$32 price target but said it will wait for the full Q2 results on August 12 before updating estimates. The firm cited the need for permanent leadership—STAAR is currently led by interim co-CEOs—and the reinstatement of formal guidance to gain greater conviction.
Regionally, China posted sequential growth and the Americas delivered double-digit gains, while EMEA sales declined modestly due to ongoing Middle East disruptions. The stock's weakness was compounded by a broader risk-off market environment that weighed on growth and small-cap healthcare names.
$STAA